Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of psoriasis.
Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.
Type:
Grant
Filed:
August 29, 2014
Date of Patent:
July 28, 2015
Assignee:
Takeda GmbH
Inventors:
Beate Schmidt, Christian Scheufler, Jürgen Volz, Martin Feth, Rolf-Peter Hummel, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Deborah Ockert, Anke Heuser, Johannes A. M. Christiaans, Geert Jan Sterk, Wiro M. P. B. Menge
Abstract: The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.
Type:
Grant
Filed:
December 15, 2010
Date of Patent:
April 28, 2015
Assignee:
Takeda GmbH
Inventors:
Dieter Flockerzi, Thomas Stengel, Alexander Mann, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Thomas Maier, Hermann Tenor, Clemens Braun, Raimund Külzer, Degenhard Marx
Abstract: The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.
Type:
Grant
Filed:
August 24, 2010
Date of Patent:
January 6, 2015
Assignee:
Takeda GmbH
Inventors:
Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Torsten Dunkern, Ewald Benediktus, Andreas Pahl, Ragna Hussong, Olaf Nimz, Matthias Mueller, Martin Viertelhaus
Abstract: The claimed subject matter relates to a device for dosing and aerosolization of aerosolizable material. The device comprises: a body with an aerosolization channel with a distal attachment portion connectable to a source of carrier gas which provides pressure pulses to the aerosolization channel; a proximal attachment portion for outputting aerosolized material and a reservoir for receiving aerosolizable material. The reservoir comprises walls and is connected in a gas-tight manner to the body and in fluid connection with the aerosolization channel. At least part of the walls of the device are self-exciting membranes that can be put into oscillation by the pressure pulses.
Type:
Grant
Filed:
April 22, 2010
Date of Patent:
December 16, 2014
Assignee:
Takeda GmbH
Inventors:
Peter Iwatschenko, Gerhard Pohlmann, Horst Windt, Wolfgang Koch, Michel Kist
Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of atopic eczema.
Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.
Type:
Grant
Filed:
September 14, 2012
Date of Patent:
October 21, 2014
Assignee:
Takeda GmbH
Inventors:
Beate Schmidt, Christian Scheufler, Juergen Volz, Martin Feth, Rolf-Peter Hummel, Armin Hatzelmann, Christof Zitt, Andrea Wohlsen, Degenhard Marx, Hans-Peter Kley, Deborah Ockert, Anke Heuser, Johannes A. M. Christiaans, Geert Jan Sterk, Wiro M. P. B. Menge
Abstract: A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.
Abstract: The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.
Type:
Application
Filed:
March 17, 2014
Publication date:
September 18, 2014
Applicant:
Takeda GmbH
Inventors:
Markus RAST, Wolfgang ISE, Gerhard BECKER, Peter SKUFCA, Henning GIESELER
Abstract: Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions.
Type:
Grant
Filed:
October 11, 2013
Date of Patent:
September 9, 2014
Assignee:
Takeda GmbH
Inventors:
Ulrich Kautz, Matthias Webel, Christian Scheufler, Rolf-Peter Hummel
Abstract: The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.
Type:
Grant
Filed:
August 24, 2010
Date of Patent:
August 26, 2014
Assignee:
Takeda GmbH
Inventors:
Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Alexander Sudau, Torsten Dunkern, Ragna Hussong, Ewald Benediktus, Andreas Pahl
Abstract: Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions.
Type:
Grant
Filed:
December 7, 2012
Date of Patent:
June 17, 2014
Assignee:
Takeda GmbH
Inventors:
Ulrich Kautz, Matthias Webel, Christian Scheufler, Rolf-Peter Hummel
Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
Abstract: The present invention provides a method for preparation of a high concentration liquid formulation (HCLF) of an antibody or a fragment thereof. The present invention also relates to a method for stabilizing an anti-CD20 antibody or a fragment thereof in a liquid pharmaceutical formulation. Furthermore, the present invention relates to a liquid pharmaceutical formulation of a veltuzumab antibody or a fragment thereof comprising at least 155 mg/mL of a veltuzumab antibody or a fragment thereof.
Type:
Application
Filed:
October 31, 2013
Publication date:
May 1, 2014
Applicant:
Takeda GmbH
Inventors:
Markus RAST, Peter SKUFCA, Wolfram STEINHILBER, Gerhard BECKER, Jurgen VOLZ, Wolfgang ISE
Abstract: The compounds of formula (1) in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.
Type:
Application
Filed:
June 12, 2012
Publication date:
April 24, 2014
Applicant:
TAKEDA GmbH
Inventors:
Thomas Stengel, Thomas Maier, Alexander Mann, Josef Stadlwieser, Dieter Flockerzi, Andreas Pahl, Ewald Benediktus, Manuela Hessmann, Tobias Kanacher, Ragna Hussong, Christof Zitt, Hans Christof Holst, Rolf-Peter Hummel, Martin Viertelhaus, Hermann Tenor, Torsten Dunkern, Armin Hatzelmann, Christian Hesslinger
Abstract: The compounds of formula (1) in which A, X, R1, R2, R3 and R7 have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.
Type:
Application
Filed:
June 12, 2012
Publication date:
April 24, 2014
Applicant:
Takeda GmbH
Inventors:
Dieter Flockerzi, Alexander Mann, Thomas Stengel, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Hermann Tenor, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Clemens Braun, Ewald Benediktus, Andreas Pahl, Raimund Kuelzer, Degenhard Marx
Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of atopic eczema.